A Three Biomarker Panel at Days 7 and 14 Can Predict Development of Grade II-IV Acute Graft-Versus-Host Disease
Sophie Paczesny(MUSC Hollings Cancer Center), John E. Levine(Icahn School of Medicine at Mount Sinai), James L.M. Ferrara(Tisch Hospital), Andrew C. Harris(Primary Children's Hospital), Joel Whitfield(University of Michigan), Bryan Fiema(University of Michigan), Samir Hanash(The University of Texas MD Anderson Cancer Center), David B. Jones(James Cook University), Sung Won Choi(University of Michigan), Shin Mineishi(University of Alabama at Birmingham), Mark Vander Lugt(Pediatrics and Genetics), Daniel R. Couriel(The University of Texas MD Anderson Cancer Center), Carrie L. Kitko(Vanderbilt University Medical Center), Gregory A. Yanik(University of Michigan), Thomas Braun(University of Michigan), Jeric Hernandez(University of Michigan), R. Pavan(University of Michigan), John Magenau(University of Michigan), Edward Peres(Henry Ford Hospital), Attaphol Pawarode(University of Michigan)
Cited by 7
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Detection and localization of surgically resectable cancers with a multi-analyte blood test
|Science|2018|2.8k
The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases
|Frontiers in Immunology|2017|612